TY - JOUR
T1 - Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression
AU - TIME-2 Study Group
AU - Campochiaro, Peter A.
AU - Khanani, Arshad
AU - Singer, Michael
AU - Patel, Sunil
AU - Boyer, David
AU - Dugel, Pravin
AU - Kherani, Saleema
AU - Withers, Barbara
AU - Gambino, Laura
AU - Peters, Kevin
AU - Brigell, Mitchell
N1 - Funding Information:
This study was funded by Aerpio Therapeutics, Cincinnati, Ohio.
Publisher Copyright:
© 2016 American Academy of Ophthalmology
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Purpose To assess the effect of AKB-9778 alone or in combination with ranibizumab in subjects with diabetic macular edema (DME). Design A phase IIa, randomized, placebo- and sham injection–controlled, double-masked clinical trial. Participants Subjects (n = 144) with decreased vision from DME and central subfield thickness (CST) ≥325 μm measured by spectral-domain optical coherence tomography (SD OCT) enrolled at 36 sites. Methods Subjects were randomized to (1) AKB-9778 monotherapy: subcutaneous AKB-9778 15 mg twice per day (BID) + monthly sham intraocular injections; (2) combination therapy: subcutaneous AKB-9778 15 mg BID + monthly 0.3 mg ranibizumab; or (3) ranibizumab monotherapy: subcutaneous placebo injections BID + monthly 0.3 mg ranibizumab. Best-corrected visual acuity (BCVA) and CST were measured at baseline and every 4 weeks. Main Outcome Measures Primary outcome measure was mean change from baseline CST at week 12. Other outcomes included BCVA, safety assessments, and Diabetic Retinopathy Severity Score (DRSS). Results At week 12, mean change from baseline CST was significantly greater in the combination group (−164.4±24.2 μm) compared with the ranibizumab monotherapy group (−110.4±17.2 μm; P = 0.008) and was 6.2±13.0 μm in the AKB-9778 monotherapy group. Mean CST at week 12 and percentage of eyes with resolved edema was 340.0±11.2 μm and 29.2%, respectively, in the combination group versus 392.1±17.1 μm and 17.0%, respectively, in the ranibizumab monotherapy group. Mean change from baseline BCVA (letters) was 6.3±1.3 in the combination group, 5.7±1.2 in the ranibizumab monotherapy group, and 1.5±1.2 in the AKB-9778 monotherapy group. The percentage of study eyes that gained ≥10 or ≥15 letters was 8.7% and 4.3%, respectively, in the AKB-9778 monotherapy group, 29.8% and 17.0%, respectively, in the ranibizumab monotherapy group, and 35.4% and 20.8%, respectively, in the combination group. Improvements in DRSS in study eyes were similar across groups, and the percentage of qualified fellow eyes with a ≥2-step change was 11.4% in all AKB-9778-treated subjects compared with 4.2% in the ranibizumab monotherapy group. AKB-9778 was well tolerated, with no clear by-treatment differences in adverse events. Conclusions Activation of Tie2 by subcutaneous injections of AKB-9778 combined with suppression of vascular endothelial growth factor (VEGF) causes a significantly greater reduction in DME than that seen with suppression of VEGF alone.
AB - Purpose To assess the effect of AKB-9778 alone or in combination with ranibizumab in subjects with diabetic macular edema (DME). Design A phase IIa, randomized, placebo- and sham injection–controlled, double-masked clinical trial. Participants Subjects (n = 144) with decreased vision from DME and central subfield thickness (CST) ≥325 μm measured by spectral-domain optical coherence tomography (SD OCT) enrolled at 36 sites. Methods Subjects were randomized to (1) AKB-9778 monotherapy: subcutaneous AKB-9778 15 mg twice per day (BID) + monthly sham intraocular injections; (2) combination therapy: subcutaneous AKB-9778 15 mg BID + monthly 0.3 mg ranibizumab; or (3) ranibizumab monotherapy: subcutaneous placebo injections BID + monthly 0.3 mg ranibizumab. Best-corrected visual acuity (BCVA) and CST were measured at baseline and every 4 weeks. Main Outcome Measures Primary outcome measure was mean change from baseline CST at week 12. Other outcomes included BCVA, safety assessments, and Diabetic Retinopathy Severity Score (DRSS). Results At week 12, mean change from baseline CST was significantly greater in the combination group (−164.4±24.2 μm) compared with the ranibizumab monotherapy group (−110.4±17.2 μm; P = 0.008) and was 6.2±13.0 μm in the AKB-9778 monotherapy group. Mean CST at week 12 and percentage of eyes with resolved edema was 340.0±11.2 μm and 29.2%, respectively, in the combination group versus 392.1±17.1 μm and 17.0%, respectively, in the ranibizumab monotherapy group. Mean change from baseline BCVA (letters) was 6.3±1.3 in the combination group, 5.7±1.2 in the ranibizumab monotherapy group, and 1.5±1.2 in the AKB-9778 monotherapy group. The percentage of study eyes that gained ≥10 or ≥15 letters was 8.7% and 4.3%, respectively, in the AKB-9778 monotherapy group, 29.8% and 17.0%, respectively, in the ranibizumab monotherapy group, and 35.4% and 20.8%, respectively, in the combination group. Improvements in DRSS in study eyes were similar across groups, and the percentage of qualified fellow eyes with a ≥2-step change was 11.4% in all AKB-9778-treated subjects compared with 4.2% in the ranibizumab monotherapy group. AKB-9778 was well tolerated, with no clear by-treatment differences in adverse events. Conclusions Activation of Tie2 by subcutaneous injections of AKB-9778 combined with suppression of vascular endothelial growth factor (VEGF) causes a significantly greater reduction in DME than that seen with suppression of VEGF alone.
UR - http://www.scopus.com/inward/record.url?scp=84969927106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969927106&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2016.04.025
DO - 10.1016/j.ophtha.2016.04.025
M3 - Article
C2 - 27236272
AN - SCOPUS:84969927106
VL - 123
SP - 1722
EP - 1730
JO - Ophthalmology
JF - Ophthalmology
SN - 0161-6420
IS - 8
ER -